- Trials with a EudraCT protocol (117)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
117 result(s) found for: Fine needle aspiration.
Displaying page 1 of 6.
EudraCT Number: 2005-000403-33 | Sponsor Protocol Number: GEICAM/2004-04 | Start Date*: 2005-06-01 |
Sponsor Name:GRUPO ESPAÑOL DE INVESTIGACIÓN EN CÁNCER DE MAMA (GEICAM) | ||
Full Title: Randomized clinical trial to evaluate the predictive accuracy of a gene expression profile-based test to select patients for preoperative taxane/anthracycline chemotherapy for stage I-III breast ca... | ||
Medical condition: Patients with histologically confirmed stage I-III invasive carcinoma of the breast for whom adjuvant chemotherapy is indicated. | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005715-22 | Sponsor Protocol Number: D6990C00001 | Start Date*: 2006-02-21 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone ma... | ||
Medical condition: postmenopausal women with hormone receptor positive early breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Prematurely Ended) NO (Completed) DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-000676-42 | Sponsor Protocol Number: PAP_RI1_2019/1 | Start Date*: 2023-01-24 |
Sponsor Name:University Center Hospital of Guadeloupe | ||
Full Title: Efficacy of metformin versus sitagliptin on benign thyroid nodules size in type 2 diabetes: a 2-years prospective multicentric study | ||
Medical condition: newly diagnosed subjects with uncomplicated T2DM and begnin TN of at least 2 cm of size, after pregnancy exclusion if women | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002662-38 | Sponsor Protocol Number: ZD1839IL/0704 | Start Date*: 2004-11-12 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A PHASE III RANDOMISED, STRATIFIED, PARALLEL-GROUP, MULTI-CENTRE, COMPARATIVE STUDY OF ZD1839 (IRESSA®) 250 MG AND 500 MG VERSUS METHOTREXATE FOR PREVIOUSLY TREATED PATIENTS WITH SQUAMOUS CELL CARC... | ||
Medical condition: squamous cell carcinoma of the head and neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) LT (Completed) EE (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-010288-17 | Sponsor Protocol Number: 1516 | Start Date*: 2009-07-13 |
Sponsor Name:Karolinska Hospital | ||
Full Title: Breast cell turnover and mammographic density in women with Polycystic Ovary Syndrome (PCOS) | ||
Medical condition: Polycystic ovary syndrome (PCOS) is the most common hormonal aberration in women of fertile age, with a prevalence of 5-10%, and is associated with chronic anovulation, hyperandrogenism and PCO mo... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005135-26 | Sponsor Protocol Number: PM0259 CA304 J1 | Start Date*: 2005-05-02 |
Sponsor Name:Pierre Fabre Médicament | ||
Full Title: ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN ... | ||
Medical condition: Stage III Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-002991-15 | Sponsor Protocol Number: SOLTI-1804 | Start Date*: 2019-11-04 |
Sponsor Name:SOLTI | ||
Full Title: HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 | ||
Medical condition: Her2‑positive, unresectable and/or metastatic breast cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2004-001904-10 | Sponsor Protocol Number: PM0259CA301J1 | Start Date*: 2004-09-15 |
Sponsor Name:Pierre Fabre Médicament represented by IRPF | ||
Full Title: Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic ... | ||
Medical condition: Treatment in locally advanced or metastatic non-small-lung cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) EE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2004-000358-21 | Sponsor Protocol Number: D7919C00706 (ZD1839IL/0706) | Start Date*: 2004-10-06 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase II Randomised, Double-blind, Placebo-controlled, Multicentre Comparative study of ZD1839 250 mg or 500 mg (Iressatm) given either continuously or concomitantly with cisplatin plus radiother... | ||
Medical condition: Untreated, unresected late stage III/IV non-metastatic head and neck squamous cell carcinoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004126-10 | Sponsor Protocol Number: GO27983 | Start Date*: 2012-04-19 | |||||||||||
Sponsor Name:Genentech Inc. | |||||||||||||
Full Title: A PHASE Ib/II STUDY OF GDC-0068 OR GDC-0980 WITH ABIRATERONE ACETATE VERSUS ABIRATERONE ACETATE IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL-BASED CHEMOTH... | |||||||||||||
Medical condition: Castration-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GR (Completed) CZ (Completed) ES (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002764-79 | Sponsor Protocol Number: RESCUE | Start Date*: 2023-04-13 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
Full Title: Diagnostic yield of Endoscopic aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr-) vs endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis ... | |||||||||||||
Medical condition: Intraductal papillary mucinous intraductal neoplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005653-22 | Sponsor Protocol Number: NL13PAR | Start Date*: 2014-08-25 |
Sponsor Name:Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital [...] | ||
Full Title: TachoSil patch application as replacement of closed suction wound drainage by parotid gland surgery; a prospective study. | ||
Medical condition: The surgical procedure of parotidectomy whereby a protid tumor is removed. During this procedure the wound surface will be covered by the surgical sealing patch TachoSil instead of the use of a c... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000693-30 | Sponsor Protocol Number: 56UCS2017 | Start Date*: 2019-11-25 | |||||||||||
Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | |||||||||||||
Full Title: EXemestane in Progesterone and/or Estrogen receptor positive epithelial ovarian cancer. A Randomized phase III Trial, EXPERT. | |||||||||||||
Medical condition: Women with confirmed high grade serous or endometrial epithelial ovarian cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003188-24 | Sponsor Protocol Number: CA184-587 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:Sahlgrenska University Hospital | |||||||||||||
Full Title: A Phase I Randomized Controlled Multicentre Trial of Isolated Hepatic Perfusion in Combination with Ipilimumab and Nivolumab in Patients with Uveal Melanoma Metastases | |||||||||||||
Medical condition: Metastatic uveal melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000810-12 | Sponsor Protocol Number: CO41101 | Start Date*: 2019-12-09 | ||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||
Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF IPATASERTIB IN COMBINATION WITH ATEZOLIZUMAB AND PACLITAXEL AS A TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR META... | ||||||||||||||||||
Medical condition: Metastatic triple-negative breast cancer (TNBC) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) FR (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Prematurely Ended) ES (Completed) FI (Completed) HU (Completed) BE (Completed) GR (Prematurely Ended) BG (Completed) DK (Completed) RO (Ongoing) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-001750-42 | Sponsor Protocol Number: CA209-214 | Start Date*: 2014-11-11 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma | |||||||||||||||||||||||
Medical condition: Advanced or metastatic renal cell carcinoma | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) BE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) DK (Trial now transitioned) NL (Trial now transitioned) IE (Trial now transitioned) PL (Completed) FR (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002721-30 | Sponsor Protocol Number: NIPU | Start Date*: 2021-01-14 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) | |||||||||||||
Medical condition: Malignant pleural mesothelioma (MPM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004792-36 | Sponsor Protocol Number: CA209-017 | Start Date*: 2012-09-11 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) Revised Protocol N... | |||||||||||||
Medical condition: Squamous cell Non-small cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Completed) ES (Ongoing) AT (Completed) HU (Completed) CZ (Completed) NO (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005019-15 | Sponsor Protocol Number: CCTL019C2202 | Start Date*: 2018-11-08 | |||||||||||
Sponsor Name:Novartis Farmacéutica, S.A. | |||||||||||||
Full Title: A Phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in pediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (N... | |||||||||||||
Medical condition: pediatric and adolescents patients with CD19positive r/r mature B-cell NHL who have relapsed after one or more prior therapies or are primary refractory. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Completed) DE (Completed) SE (Ongoing) DK (Completed) NO (Completed) AT (Completed) GB (GB - no longer in EU/EEA) NL (Completed) FI (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000727-25 | Sponsor Protocol Number: 47582 | Start Date*: 2017-03-28 |
Sponsor Name:Isala Klinieken | ||
Full Title: The effect of ARTISS on latissimus dorsi donor site seroma formation after breast reconstruction: a randomised controlled trial. | ||
Medical condition: The aim of this study is to investigate the effect of the fibrin sealant ARTISS compared with our standard care on total volume of donor site seroma after harvesting a LD in immediate breast recons... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
